Nadilaz (Azelastine Hydrochloride, Fluticasone Propionate)

Azelastine blocks H1 histamine receptors, preventing the immediate allergic response, while fluticasone binds glucocorticoid receptors to suppress inflammatory cytokines. Together they provide rapid symptom relief and reduce underlying nasal inflammation.

The specific dosing regimen for Nadilaz is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product label.

Safety data for Nadilaz in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the Nadilaz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Nadilaz combines an antihistamine (azelastine) and a corticosteroid (fluticasone) in a single nasal spray, offering both rapid symptom relief and anti‑inflammatory action. Compared with single‑agent antihistamine sprays, it may provide greater control of congestion, while offering convenience over using two separate products.

Store Nadilaz at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and do not freeze the product.

Nadilaz is administered as an intranasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into each nostril, and spray the prescribed number of sprays while breathing in gently. The device should be primed according to the manufacturer’s instructions before first use.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, vision changes or increased intra‑ocular pressure, adrenal suppression with prolonged use, and opportunistic fungal infections of the sinuses. Patients should seek immediate medical attention if any of these occur.

Nadilaz should be avoided by individuals with known hypersensitivity to azelastine, fluticasone, or any of the formulation’s excipients. It is also contraindicated in patients who have had recent nasal surgery or trauma until the nasal mucosa has healed.